RT Journal Article
SR Electronic
T1 Immunoglobulin E as a biomarker for the overlap of atopic asthma and chronic obstructive pulmonary disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19004333
DO 10.1101/19004333
A1 Hersh, Craig P.
A1 Zacharia, Soumya
A1 Arivu Chelvan, Ram Prakash
A1 Hayden, Lystra P.
A1 Mirtar, Ali
A1 Zarei, Sara
A1 Putcha, Nirupama
A1 the COPDGene Investigators
YR 2019
UL http://medrxiv.org/content/early/2019/08/12/19004333.abstract
AB Asthma-COPD overlap (ACO) is a common clinical syndrome, yet there is no single objective definition. We hypothesized that Immunoglobulin E measurements could be used to refine the definition of ACO. In baseline plasma samples from 2870 subjects in the COPDGene Study, we measured total IgE levels and specific IgE levels to six common allergens. Compared to usual COPD, subjects with ACO had higher total IgE levels (median 67.0 vs 42.2 IU/ml) and more frequently had at least one positive specific IgE (43.5 vs 24.5%). We previously used a strict definition of ACO in subjects with COPD, based on self-report of a doctor’s diagnosis of asthma before the age of 40. This strict ACO definition was refined by the presence of atopy, determined by total IgE >100 IU/ml or at least one positive specific IgE, as was a broader definition of ACO based on any asthma history. Subjects will all three ACO definitions were younger (mean age 60.0-61.3), were more commonly African American (36.8-44.2%), had a higher exacerbation frequency (1.0-1.2 in the past year), and had more airway wall thickening on quantitative analysis of chest CT scans. Among subjects with clinical ACO, 37-46% did not have atopy; these subjects had more emphysema on chest CT scan. Based on associations with exacerbations and CT airway disease, IgE did not clearly improve the clinical definition of ACO. However, IgE measurements could be used to subdivide subjects with atopic and non-atopic ACO, who might have different biologic mechanisms and potential treatments.Competing Interest StatementDr. Hersh reports grant support from the National Institutes of Health and Novartis for this study. He reports grant support from Boehringer-Ingelheim and personal fees from AstraZeneca and 23andMe outside of this study. None of the other authors report any disclosures related to this study.Funding StatementFunded by NIH grants R01HL130512, R01HL125583, K23HL123594, P01HL132825, U01HL089856, and U01HL089897 and a grant from Novartis. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee comprised of AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sunovion.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesCOPDGene Study data is available on dbGAP, accession phs000179.ACOasthma-COPD overlapCTcomputed tomographyFEV1forced expiratory volume in 1 secFVCforced vital capacityIgEimmunoglobulin E